Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
暂无分享,去创建一个
A. Nairn | G. Kerchner | A. Wagner | M. Greicius | G. Davidzon | J. Quinn | T. Wyss-Coray | V. Henderson | C. V. van Dyck | E. Mormino | K. Poston | Y. Le Guen | Betty Lind | C. Fredericks | Divya Channappa | K. Younes | S. Sha | K. Andreasson | M. Vandijck | N. Kasireddy | Marian Shahid | Gabriel Kennedy | Alexandra N. Trelle | M. Yutsis | T. Montine | Nicole K. Corso | N. Le Bastard | Lu Tian | Qian Wang | E. N. Wilson | I. Feinstein | A. Trelle | C. Young | Javier Ramos Benitez | Michelle S. Swarovski | Nandita M. Kasireddy | Malia A. Belnap | V. Ramírez | Irina Skylar-Scott | Maya V. Yutsis | F. Longo | B. Lind | E. Wilson | Michelle Swarovski | Yann Le Guen | Malia A Belnap
[1] S. Lincoln,et al. Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans , 2022, EBioMedicine.
[2] K. Blennow,et al. Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change , 2022, Acta Neuropathologica.
[3] K. Blennow,et al. Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults , 2022, Annals of neurology.
[4] Lin F. Yang,et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet. Public health.
[5] W. M. van der Flier,et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 , 2021, Alzheimer's Research & Therapy.
[6] M. Greicius,et al. Plasma Biomarkers of Tau and Neurodegeneration During Major Cardiac and Noncardiac Surgery. , 2021, JAMA neurology.
[7] O. Hansson,et al. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays , 2021, Neurology.
[8] C. Jack,et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. , 2021, JAMA neurology.
[9] K. Blennow,et al. Association of plasma P-tau181 with memory decline in non-demented adults , 2021, Brain communications.
[10] O. Hansson,et al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects , 2021, Brain : a journal of neurology.
[11] M. Carrillo,et al. The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[12] K. Blennow,et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[13] K. Blennow,et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.
[14] K. Blennow,et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease , 2021, JAMA neurology.
[15] Valerie A. Carr,et al. Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease , 2021, Neurology.
[16] M. Carrasquillo,et al. Plasma Biomarkers of Alzheimer’s Disease in African Americans , 2020, Journal of Alzheimer's disease : JAD.
[17] K. Blennow,et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected , 2020, EMBO molecular medicine.
[18] K. Blennow,et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.
[19] K. Blennow,et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline , 2020, Acta Neuropathologica.
[20] J. Trojanowski,et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative , 2020, Molecular Psychiatry.
[21] K. Blennow,et al. Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum , 2020, medRxiv.
[22] Nick C Fox,et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study , 2020, Molecular Psychiatry.
[23] K. Blennow,et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.
[24] K. Blennow,et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.
[25] L. Tian,et al. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. , 2020, Brain : a journal of neurology.
[26] Valerie A. Carr,et al. Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults , 2020, bioRxiv.
[27] C. Jack,et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.
[28] Linda J. C. van Waalwijk van Doorn,et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[29] P. Snyder,et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic , 2017, Alzheimer's & Dementia.
[30] C. Jack,et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.
[31] Keith A. Johnson,et al. The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials , 2014, Neuron.
[32] Cindee M. Madison,et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.
[33] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[34] K. Blennow,et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.
[35] P. Cohen,et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.
[36] R. Castellani,et al. Alzheimer disease. , 2010, Disease-a-month : DM.
[37] K. Blennow,et al. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.
[38] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..